Please login to the form below
biosimilars
This page shows the latest biosimilars news and features for those working in and with pharma, biotech and healthcare.
Alexion eyes Soliris combo with $930m deal to buy Achillion
The drug currently accounts for more than 80% of Alexion’s sales, but is facing the threat of biosimilar competition. ... While Alexion recently claimed a patent extension in the US until 2027, that is subject to a challenge by Amgen that – if
Latest news
-
Roche reports continued growth in Q3, despite biosimilar competition
In Europe, sales were down 1% thanks to the competition from biosimilars for Herception and Rituxan, but there was growth reported in the uptake of Ocrevus, Perjeta, Tecentriq, Alecensa and Hemlibra.
-
Allergan investors back AbbVie deal, but is a tax charge looming?
facing competition from cheaper biosimilars.
-
In a U-turn, ICER takes more positive view of AbbVie’s Rinvoq
The finding dented AbbVie’s hopes of growing sales of Rinvoq to offset the anticipated loss of Humira revenues to biosimilar competitors. ... Given that biosimilar competitors for Humira are on the horizon, the finding suggests Pfizer could struggle to
-
Roche’s MabThera beats incumbent drug in pemphigus vulgaris phase 3
European sales of MabThera fell by 36% in the first half of 2019 in the face of competition from biosimilars.
-
UCB gets bigger in rare diseases with $2.1bn purchase of Ra Pharma
If successful, this could allow a lower-cost biosimilar of the drug to reach the US market in 2021, although Alexion is currently claiming patent protection until 2027 in that market.
More from news
Approximately 135 fully matching, plus 325 partially matching documents found.
Latest Intelligence
-
The Golden Goose
Biosimilar fail. Another stumbling block has been our over-reliance on market-based solutions to this problem, ie, generics. ... The thinking was at that time we’d solved the biosimilar problem, and here we are nine years later saying, no, we haven’t.
-
Transitions in healthcare
Switching from an originator biologic to a cheaper biosimilar. These are all examples of the kind of treatment transitions patients experience that can be supported by Patient Support Programmes.
-
It’s not the end of the world, is it?
Whether we market branded products that offer no real superiority over generics, biosimilars or me-toos or we sell innovative products whose price differential is not financially justified, much of what
-
Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019
It will compete with numerous treatment modalities, including entrenched biological agents and biosimilar biologicals.
-
Drug launches to watch in 2019
The world’s biggest selling drug, Humira, lost its market exclusivity in Europe to biosimilar competition in 2018, and AbbVie is well aware of the impending US patent expiry in 2022. ... Finally, 2019 will see a rapid increase in the uptake of Humira
More from intelligence
Approximately 11 fully matching, plus 57 partially matching documents found.
Latest appointments
-
New hires at Bayer, Eisai and Accord Healthcare
and biosimilar specialists,” he added.
-
Ashfield, Health Unlimited and Ashley Communications add to their teams
Van Weperen was most recently at diabetes giant Novo Nordisk, where he worked on delivering insulin and GLP1 biosimilar defence strategies, leading Novo’s UK diabetes team.
-
Lilly bolsters its oncology team
Furthermore, she has been on the forefront of research in oncology vaccines, immuno-oncology and biosimilars, giving her the unique expertise that will be pivotal in helping us continue to develop
-
PharmaLex appoints Zabin Younes as associate director
She joins the group as an associate director and arrives from ERA Consulting - a biopharmaceutical consultancy based in the UK - where she picked up experience in the biosimilar development lifecycle. ... With experience spanning over 15 years, Younes’
-
GW Pharmaceuticals strengthens research and development team
Knappertz has previously held several leadership positions including vice president of clinical development for multiple sclerosis, oncology and biosimilar products at Teva, and numerous clinical and medical roles at Bayer and
More from appointments
Approximately 1 fully matching, plus 15 partially matching documents found.
Latest from PMHub
-
Three strategies for managing loss of exclusivity successfully
In late 2017, the FDA approved Admelog, Sanofi’s biosimilar of Humalog. Eli Lilly responded by launching an LOE strategy that tapped into patients’ desire for a stable treatment plan.
-
Webcast: Navigating new frontiers: Ways to find space in the future RA market
in the European RA market, where their convenient oral administration advantage may override cost considerations that would otherwise favour biosimilar uptake. ... Uptake curve of JAKS compared to other new entrants and biosimilars.
-
Live webinar: Navigating new frontiers: Ways to find space in the future RA market
their convenient oral administration advantage may override cost considerations that would otherwise favour biosimilar uptake. ... Uptake curve of JAKs compared to other new entrants and biosimilars.
-
NHS medicines optimisation milestone
Tackling variations in the uptake of biosimilars locally has been a key focus for RMOCs. ... The best biologics agenda and pharma. In line with the Commissioning Framework for Biological Medicines, NHS England, NHS Improvement and NHS Clinical
-
New local NHS models help to deliver integrated care
A classic example of the way in which this can be achieved can be seen in the development of some biosimilar medicines, which are moving away from infusion to subcutaneous injections
More from PMHub
Approximately 13 fully matching, plus 23 partially matching documents found.
Featured jobs
- Senior / Principal Medical Writers wanted - MedComms - Various U...
-
Excellent Remuneration Packages
-
Senior Copywriter
-
Salary TBC
- Senior Medical Writer – Medical Communications – North West – In...
-
Excellent Remuneration Package
- Senior Account Manager / Account Director - MedComms - London
-
Highly competitive salary &package
-
Account Director, Medical Education
-
Salary TBC
- Experienced / Senior Medical Writer - Excellent Progression Oppo...
-
Excellent Salary and Benefits on offer
-
Senior Medical Writer
-
Salary TBC
- Account Director, Healthcare Communications Agency
-
£54, 000- £60, 000
- Editorial Assistants - Medical Communications agency - Cheshire
-
Excellent Remuneration Package
-
Senior Medical Writer
-
Competitive salary plus benefits
Subscribe to our email news alerts
- Leading AstraZeneca’s return to growth in Europe
- Novartis bags US okay for Lucentis follow-up Beovu in wet AMD
- GSK forms cell therapy R&D pact with star-studded biotech
- Bayer/J&J claim new FDA okay for clot drug Xarelto
- Allergan investors back AbbVie deal, but is a tax charge looming?
- Bayer opens AI-enabled drug discovery center in UK
- Spotlight interview: 15 minutes on PR in pharma
- Changing healthcare, one film at a time
- Faisal Ahmed joins healthcare comms agency Sudler London
- Red Consultancy appoints MD in its health division
- Takeda offloads select portfolio to Acino ahead of Shire takeover
- Wilmington Healthcare appoints new consultants
PMHub
BASTARD . LONDON
BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...
Latest intelligence
- eyeforpharma Marketing and Customer Innovation Europe
- By Richard Springham...
- The Golden Goose
- Why it’s so hard for the US to curb runaway drug prices...
- What is changing in cardiovascular disease care?
- Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma...
Quick links
Infographics
